Generation and Applications of Human Monoclonal Antibodies to Herpes Viruses
Human cytomegalovirus (CMV) and varicella zoster virus (VZV) are two herpes viruses associated with severe infections in immunosuppressed or immunodeficient patients. For example, bone marrow transplant recipients are especially susceptible to CMV infections and juvenile leukemia patients are vulnerable to VZV infections (Gershon, 1980; Meyers et al, 1986). Three approaches are used to control these infections: antiviral drugs, active immunization with attenuated viruses, and passive immunization with hyperimmune immunoglobulin preparations. Two nucleoside analogs, 9-(1,3-dihydroxy-2-propoxymethyl) guanine (DHPG) and acyclovir (ACV), have recently been studied for treatment of CMV infections. Although DHPG (Koretz, et al, 1986) and, in some cases, ACV (Balfour, et al, 1982), have some efficacy in treating CMV-infected patients, their use is limited by toxic effects and neither is effective against CMV pneumonia (Wade, et al, 1982; Myers, 1985). Antiviral drug therapy against severe VZV infections, however, is more promising. Both ACV and vidarabine, for example, are effective in reducing the severity of VZV infections in immunosuppressed patients (Vildé, et al, 1986).
KeywordsVaricella Zoster Virus Herpes Virus Human Monoclonal Antibody Fusion Efficiency Human Lymphoblastoid Cell Line
Unable to display preview. Download preview PDF.
- Foung, S. K. H., and Lennette, E. T., 1986, A strategy to produce human monoclonal antibodies to herpes viruses in: “Human Herpes virus Infections: Pathogenesis, Diagnosis, and Treatment,” C. Lopez and B. Roizman, eds, Raven Press, New York.Google Scholar
- Foung, S, K. H., Perkins, S., Arvin, A., Lifson, J., Mohagheghpour, N., Fishwild, D., Grumet, F. C, and Engleman, E. G., 1985a, Production of human monoclonal antibodies using a human-mouse fusion partner in: “Human Hybridomas and Monoclonal Antibodies,” E.G. Engleman, S.K. Foung, J.W. Larrick, and A. Raubitschek, eds., Plenum Press, New York.Google Scholar
- Gershon, A. A., 1985, Live attenuated varicella vaccine in: “The Herpes viruses, vol. 4,” B. Roizman and C. Lopez, eds., Plenum Press, New York.Google Scholar
- Meyers, J. P., 1985, Cytomegalovirus infection after organ allografting: prospects for immunoprophylaxis in: “The Herpes viruses, vol. 4,” B. Roizman and C. Lopez, eds., Plenum Press, New York.Google Scholar
- Nowinski, R., Boglund, C., Lane, J., Lastrum, M., Bernstein, I., Young, W., Hakomori, S., Hall, L., and Cooney, M., 1980, Production of antibody to tetanus toxoid by continuous human lymphoblastoid cell lines, Science, 199:1439.Google Scholar
- Plotkin, S. A., 1985, CMV vaccines in: “The Herpes viruses, vol. 4,” B. Roizman and C. Lopez, eds., Plenum Press, New York.Google Scholar
- Takahashi, M., Asano, Y., Kamiya, H., and Baba, K., 1986, Experience with a live varicella vaccine In: “Human Herpes virus Infections: Pathogenesis, Piagnosis, and Treatment, C. Lopez and B. Roizman, eds., Raven Press, New York.Google Scholar